LivaNova (LIVN) – Research Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for LivaNova (NASDAQ: LIVN):

• 11/5/2026 – LivaNova had its price target raised by Robert W. Baird from $95.00 to $111.00. They now have an “outperform” rating on the stock.
• 11/4/2026 – LivaNova was given a new $115.00 price target by Mizuho.
• 11/4/2026 – LivaNova was given a new $120.00 price target by Raymond James Financial.
• 11/4/2026 – LivaNova had its “buy” rating reaffirmed by Jefferies Financial Group.
• 11/4/2026 – LivaNova had its price target raised by Needham & Company LLC from $93.00 to $112.00. They now have a “buy” rating on the stock.
• 10/27/2026 – LivaNova was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 10/7/2026 – LivaNova was upgraded by Barclays to “strong-buy”.
• 10/6/2026 – LivaNova is now covered by Barclays. They set an “overweight” rating and a $105.00 price target on the stock.

LivaNova Trading Down 3.2%

NASDAQ:LIVN opened at $91.14 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.46 and a quick ratio of 1.21. The firm has a 50-day moving average of $79.08 and a 200-day moving average of $73.40. The company has a market cap of $5.02 billion, a PE ratio of 30.38 and a beta of 0.91. LivaNova PLC has a one year low of $48.82 and a one year high of $99.38.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17. The company had revenue of $393.15 million for the quarter, compared to analyst estimates of $381.13 million. LivaNova had a net margin of 13.01% and a return on equity of 16.10%. The firm’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.11 EPS. As a group, equities research analysts expect that LivaNova PLC will post 3.78 EPS for the current fiscal year.

Insider Activity at LivaNova

In related news, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the transaction, the director owned 7,488 shares of the company’s stock, valued at $609,672.96. The trade was a 23.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total value of $273,035.00. Following the transaction, the director directly owned 4,434 shares in the company, valued at approximately $345,896.34. The trade was a 44.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 7,450 shares of company stock valued at $591,839. Company insiders own 0.35% of the company’s stock.

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.